COMPARATIVE IN VITRO DRUG RELEASE STUDIES OF GLIMEPIRIDE SOLID DISPERSIONS & METFORMIN MICROCAPSULESAbstract
The study was undertaken to compare the efficacy and safety of Glimepiride and Metformin in the management of patients with type 2 DM. The present invention is directed to a pharmaceutical composition in the form of a capsule with increased bioavailability as well as the process for obtaining said composition. The tablet of the present invention comprises two active ingredients comprising two oral hypoglycemic agents: one phase with a sulphonylurea, such as immediate release Glimepiride and second phase with a biguanide, such as extended release Metformin hydrochloride (Metformin HCL). This composition of capsule, which can include over 500mg of Metformin HCL (i.e. up to daily requirements of each patient), is to be orally administered once or twice a day. The combination of these hypoglycemic agents has a synergic effect.Finally we can explain that the availability of Metformin-Glimepiride combination can minimize the effects of diabetic conditions. From the complete work we assume that these hypoglycemic agents have a synergistic effect and therefore a greater effectiveness in controlling the blood glucose level in patients with type II diabetes mellitus.
B.V. Ramana*, D.S. Spandana Anand P, C. Triveni, V. Pavan Kumar, P. Venkateshwar Reddy and U. Chandra Sekhar
Dr. K.V. Subba Reddy Institute of Pharmacy, Kurnool- 518 002, Andhra Pradesh, India
18 June, 2013
27 July, 2013
22 October, 2013
01 November, 2013